ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research.

Product information

CAS Number: 1377897-01-2

Molecular Weight: 339.43

Formula: C21H25NO3

Chemical Name: (4-hydroxy-3, 4-dihydro-1H-isoquinolin-2-yl)-[3-(3-hydroxy-3-methylbutyl)phenyl]methanone

Smiles: CC(C)(O)CCC1C=CC=C(C=1)C(=O)N1CC2=CC=CC=C2C(O)C1

InChiKey: HYVUFYJZMRRTOP-UHFFFAOYSA-N

InChi: InChI=1S/C21H25NO3/c1-21(2,25)11-10-15-6-5-8-16(12-15)20(24)22-13-17-7-3-4-9-18(17)19(23)14-22/h3-9,12,19,23,25H,10-11,13-14H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

ERD03 inhibits the binding of G-rich RNA and EXOSC3 with ~18% inhibition at 50 μM. ERD03 (50 μM; 5 days) causes significant spinal curvature and recapitulates PCH1B phenotype in development in zebrafish embryos. ERD03 (50 μM) induces a ~6-fold upregulation of ataxin1b mRNA and results in a minor accumulation of ataxin1a mRNA in embryos. ERD03 induces an atrophy of the zebrafish cerebellum and results in zebrafish cerebella half the size of control brains in DMSO.

Products are for research use only. Not for human use.